• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Neptune Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results

    7/17/23 5:38:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NEPT alert in real time by email

    Consolidated revenues for fiscal 2023 totaled $52.6 million, an increase of $3.8 million or 7.8% as compared to $48.8 million for fiscal 2022

    Q4 net sales $12.1 million, up 5% from last year's $11.5 million

    Sprout maintained a top 3 brand position on Amazon in fiscal 2023 and strong sales levels in all periods nationally1

    Sprout was available in 90% of footprint the Organic Baby Food market across all 50 U.S. states and Canada

    Company to host a conference call at 5:00 p.m. (Eastern Time) on Tuesday, July 18, 2023

    LAVAL, QC, July 17, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced its financial and operating results for the three-month and twelve-month periods ending March 31, 2023.

    Neptune Wellness Logo (CNW Group/Neptune Wellness Solutions Inc.)

    "Neptune Wellness Solutions has made significant strides in fiscal 2023, demonstrating our unwavering commitment to growth and innovation in the consumer-packaged goods space. Our brands, Sprout and Biodroga, have been instrumental in propelling our platform this year," said Michael Cammarata, CEO and President of Neptune Wellness Solutions. "With Sprout's expansion into the Organic Baby Food market across all 50 U.S. states and Canada, we are strategically focused on delivering high-quality, sustainable products to our customers. We're excited about the cost savings and efficiencies we've achieved, but we acknowledge there's more work to be done. As we transition into fiscal 2024, we remain dedicated to further optimizing our operations and improving our financial position. We recognize there are risks ahead, but we are confident that the platform we are building is the right move for our future."

    Raymond P. Silcock, Chief Financial Officer of Neptune added, "As well as growing our key focus business areas of Sprout and Biodroga, Neptune is focused on further reducing corporate costs, managing expenses and improving its liquidity position into fiscal 2024. We are focused on further optimizing the supply chain for Sprout, and we have restructured production planning with $2.6 million in cost savings for the remainder of fiscal 2023 expected."

    __________________________

    1 Nielsen data from 52 weeks to 4/22/23.

    Fourth Quarter and Full Year Financial Highlights:

    • Fiscal fourth quarter revenue totaled $12.1 million, as compared to $11.5 million for the same period last year.
    • Fiscal year 2023 revenue totaled $52.6 million, an increase of $3.8 million or 7.8% as compared to $48.8 million for fiscal 2022.
    • Reported gross profit (loss) of $(2.5) million for fiscal 2023, compared to $(7.5) million for fiscal 2022, an improvement of $5.0 million or 67%.
    • Reported gross profit (loss) for the fourth fiscal quarter of $(2.6) million compared to $(5.7) million for the prior corresponding period, an improvement of $3.1 million or 55%.
    • Reported fourth quarter net profit (loss) of $(44.5) million compared to a reported net profit (loss) of $(36.7) million in the comparable period in fiscal 2022 and reported fiscal year 2023 net profit (loss) of $(88.8) million compared to a net profit (loss) of $(84.4) million for the fiscal year 2022.
    • Adjusted EBITDA (non-GAAP)1 profit (loss) for fiscal year 2023 was $(39.7) million compared to an Adjusted EBITDA (non-GAAP)1 profit (loss) of $(53.3) million for the fiscal year 2022, an improvement of 26%.
    • Cash and cash equivalents were $2.0 million, as of March 31, 2023.

    Fourth Quarter & Recent Business Highlights:

    • Expanded Sprout Organics CoComelon co-branded organic baby food into Target stores.
    • Sprout extended distribution so its products are now available in 90% of Organic Baby Food footprint in the market, all 50 U.S. states and Canada, with recent launch into Loblaws, the largest grocer in Canada and shipping direct-to-consumers through the Sprout website.
    • Sprout continued to optimize its supply chain and expects to achieve $2.6 million in cost savings for the remainder of calendar 2023 due to restructured production planning.
    • Sprout's sales are maintaining a top 3 brand position on Amazon in fiscal 2023 and strong sales levels in all periods nationally, according to Nielsen data.
    • On a fiscal year to date basis, Sprout's fill rate has improved to 90%, compared to 73% for the same period last year.
    • At +12%, Sprout's sales growth outperformed the Total Shelf Stable Baby Food category2.
    • Biodroga reported gross margins of 28%, up from 25% the same period year prior. Revenue for fiscal 2023 totaled $14.9 million, an increase of 18% as compared to fiscal 2022.

    Fourth Quarter & Recent Corporate Highlights:

    • Announced closing of debt financing for $4 million, improving the Company's capital position.
    • Announced an accounts receivable factoring facility of up to $7.5 million for its Sprout Organics baby food brand.
    • Extended the maturity of its existing $13 million secured promissory note for Sprout with Morgan Stanley Expansion Capital.

    Conference Call Details:

    The Company will host a conference call at 5:00 p.m. (Eastern Time) on Tuesday, July 18, 2023, to discuss these results. The conference call will be webcast live and can be accessed by registering on the Events and Presentations portion of Neptune's Investor Relations website at www.investors.neptunewellness.com. The webcast will be archived for approximately 90 days.

    ___________________________

    2 Nielsen data from 13 weeks to 4/1/23



    ADJUSTED EBITDA

    Although the concept of Adjusted EBITDA is not a financial or accounting measure defined under US GAAP and it may not be comparable to other issuers, it is widely used by companies. Neptune obtains its Adjusted EBITDA measurement by adding to net loss, net finance costs (income) and depreciation and amortization, and income tax expense (recovery). Other items such as stock-based compensation, non-employee compensation related to warrants, litigation provisions, business acquisition and integration costs, signing bonuses, severances and related costs, impairment losses on non-financial assets, write-downs of non-financial assets, revaluations of derivatives, system migration, conversion and implementation, and other changes in fair values are also added back. The exclusion of net finance costs (income) eliminates the impact on earnings derived from non-operational activities. The exclusion of depreciation and amortization, stock-based compensation, non-employee compensation related to warrants, litigation provisions, impairment losses, write-downs revaluations of derivatives and other changes in fair values eliminates the non-cash impact, and the exclusion of acquisition costs, integration costs, signing bonuses, severance and related costs, costs. From time to time, the Company may exclude additional items if it believes doing so would result in a more effective analysis of underlying operating performance. Adjusting for these items does not imply they are non-recurring.

    About Neptune Wellness Solutions Inc.

    Neptune is a consumer-packaged goods company that aims to innovate health and wellness products. Founded in 1998 and headquartered in Laval, Quebec, the Company focuses on developing a portfolio of high-quality, affordable consumer products that align with the latest market trends for natural, sustainable, plant-based and purpose-driven lifestyle brands. The Company's products are available in more than 27,000 retail locations and include well-known organic food and beverage brands such as Sprout Organics, Nosh, and Nurturme, as well as nutraceuticals brands like Biodroga and Forest Remedies. With its efficient and adaptable manufacturing and supply chain infrastructure, the Company can quickly respond to consumer demand, and introduce new products through retail partners and e-commerce channels. Please visit neptunewellness.com for more details.

    Disclaimer – Safe Harbor Forward–Looking Statements

    This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the ability to achieve cost savings and efficiencies and optimizing supply chains.

    Consolidated Balance Sheets

    (In U.S. dollars)





    As at



    As at





    March 31,

    2023



    March 31,

    2022

    Assets









    Current assets:









    Cash and cash equivalents



    $1,993,257



    $8,726,341

    Short-term investment



    17,540



    19,255

    Trade and other receivables



    7,507,333



    7,599,584

    Prepaid expenses



    1,025,969



    3,983,427

    Inventories



    13,006,074



    17,059,406

    Total current assets



    23,550,173



    37,388,013











    Property, plant and equipment



    1,403,264



    21,448,123

    Operating lease right-of-use assets



    1,941,347



    2,295,263

    Intangible assets



    1,607,089



    21,655,035

    Goodwill



    2,426,385



    22,168,288

    Total assets



    $30,928,258



    $104,954,722











    Liabilities and Equity









    Current liabilities:









    Trade and other payables



    $27,051,561



    $22,700,849

    Current portion of operating lease liabilities



    339,620



    641,698

    Loans and borrowings



    7,538,369



    —

    Deferred revenues



    —



    285,004

    Provisions



    2,948,340



    1,118,613

    Liability related to warrants



    3,156,254



    5,570,530

    Total current liabilities



    41,034,144



    30,316,694











    Operating lease liabilities



    2,017,888



    2,063,421

    Loans and borrowings



    15,412,895



    11,648,320

    Other liability



    24,000



    88,688

    Total liabilities



    58,488,927



    44,117,123











    Shareholders' Equity (Deficiency):









    Share capital - without par value (11,996,387 shares issued and outstanding as of

         March 31, 2023; 5,560,829  shares issued and outstanding as of March 31, 2022)



    321,946,102



    317,051,125

    Warrants



    6,155,323



    6,079,890

    Additional paid-in capital



    58,138,914



    55,980,367

    Accumulated other comprehensive loss



    (14,538,830)



    (7,814,163)

    Deficit



    (383,641,363)



    (323,181,697)

    Total equity (deficiency) attributable to equity holders of the Company



    (11,939,854)



    48,115,522











    Non-controlling interest



    (15,620,815)



    12,722,077

    Total shareholders' equity (deficiency)



    (27,560,669)



    60,837,599











    Commitments and contingencies









    Subsequent events









    Total liabilities and shareholders' equity (deficiency)



    $30,928,258



    $104,954,722

    See accompanying notes to the consolidated financial statements.



    Consolidated Statements of Loss and Comprehensive Loss

    (In U.S. dollars)















    Years ended







    March 31,

    2023



    March 31,

    2022













    Revenue from sales, net of excise taxes

         of $643,476 (2022 - $1,877,543)



    $51,744,817



    $47,695,828

    Royalty revenues



    818,584



    1,019,861

    Other revenues



    51,937



    81,435

    Total revenues



    52,615,338



    48,797,124













    Cost of sales other than impairment loss on inventories,

         net of subsidies of nil (2022 - $924,644)



    (49,591,156)



    (52,561,404)

    Impairment loss on inventories



    (5,498,347)



    (3,772,066)

    Total Cost of sales



    (55,089,503)



    (56,333,470)

    Gross profit (loss)



    (2,474,165)



    (7,536,346)













    Research and development expenses



    (484,224)



    (880,151)

    Selling, general and administrative expenses, net of subsidies

         of nil (2022 - $99,840 )



    (46,424,295)



    (60,538,424)

    Impairment loss related to intangible assets



    (17,979,060)



    (1,527,000)

    Impairment loss related to property, plant and equipment



    —



    (14,765,582)

    Impairment loss on assets held for sale



    (15,346,119)



    —

    Impairment loss on right of use assets



    (424,454)



    —

    Impairment loss related to goodwill



    (19,542,436)



    (3,288,847)

    Net gain (loss) on sale of property, plant and equipment



    (172,945)



    6,469

    Loss from operating activities



    (102,847,698)



    (88,529,881)













    Finance income



    1,445



    7,123

    Finance costs



    (3,824,030)



    (2,143,978)

    Loss on issuance of derivatives



    (3,156,569)



    —

    Foreign exchange gain (loss)



    6,434,510



    (685,708)

    Change in revaluation of marketable securities



    —



    (107,203)

    Gain on revaluation of derivatives



    14,709,805



    7,035,118

    Loss on settlement of liability



    (120,021)



    —







    14,045,140



    4,105,352

    Loss before income taxes



    (88,802,558)



    (84,424,529)













    Income tax recovery



    —



    —

    Net loss



    (88,802,558)



    (84,424,529)













    Other comprehensive income (loss)









    Net change in unrealized foreign currency gains (losses)

         on translation of net investments in foreign operations

         (tax effect of nil for all periods)



    (6,724,667)



    750,248

    Total other comprehensive income (loss)



    (6,724,667)



    750,248













    Total comprehensive loss



    $(95,527,225)



    $(83,674,281)













    Net loss attributable to:









    Equity holders of the Company



    $(60,459,666)



    $(74,971,745)

    Non-controlling interest



    (28,342,892)



    (9,452,784)

    Net loss



    $(88,802,558)



    $(84,424,529)













    Total comprehensive loss attributable to:









    Equity holders of the Company



    $(67,184,333)



    $(74,218,802)

    Non-controlling interest



    (28,342,892)



    (9,455,479)

    Total comprehensive loss



    $(95,527,225)



    $(83,674,281)













    Basic loss per share attributable to:









    Common Shareholders of the Company



    $(5.12)



    $(15.54)













    Diluted loss per share attributable to:









    Common Shareholders of the Company



    $(5.12)



    $(15.54)













    Basic and diluted weighted average number of common shares



    11,812,337



    4,824,336



    SELECTED CONSOLIDATED FINANCIAL INFORMATION

    The following table sets out selected consolidated financial information and are prepared in accordance with US GAAP.





    Three-month periods ended

    Twelve-month periods ended





    March 31,

    2023



    March 31,

    2022



    March 31,

    2023



    March 31,

    2022









    Recasted







    Recasted





    $



    $



    $



    $

    Total revenues



    12.147



    11.532



    52.615



    48.797

    Adjusted EBITDA1



    (12.963)



    (12.762)



    (39.660)



    (53.258)

    Net loss



    (44.513)



    (36.662)



    (88.803)



    (84.425)

    Net loss attributable to equity holders of the

         Company



    (26.566)



    (31.942)



    (60.460)



    (74.972)

    Net loss attributable to non-controlling interest



    (17.947)



    (4.720)



    (28.343)



    (9.453)

    Basic and diluted loss per share



    (3.74)



    (7.47)



    (7.52)



    (17.50)

    Basic and diluted loss attributable

         to common shareholders of the Company



    (2.23)



    (6.51)



    (5.12)



    (15.54)

     





    As at

    March 31, 2023



    As at

    March 31, 2022



    As at

    March 31, 2021





    $



    $



    $

    Total assets



    30.928



    104.955



    186.948

    Working capital2



    (17.484)



    7.071



    54.718

    Non-current financial liabilities



    17.455



    13.800



    14.593

    (Deficiency) equity attributable to equity holders of the Company



    (11.940)



    48.116



    115.368

    (Deficiency) equity attributable to non-controlling interest



    (15.621)



    12.722



    22.178

    1  The Adjusted EBITDA is a non-GAAP measure. It is not a standard measure endorsed by US GAAP requirements. A reconciliation to the Company's net loss is presented below. In the quarter ended September 30, 2022, the Company recasted comparative Adjusted EBITDA to conform to its current definition. As a result, the following adjustments were removed in the current and comparative quarters: litigation provisions, business acquisition and integration costs, signing bonus, severance and related costs, and write-down of inventories and deposits.

    2 Working capital is calculated by subtracting current liabilities from current assets. Because there is no standard method endorsed by US GAAP, the results may not be comparable to similar measurements presented by other public companies. Current assets as at March 31, 2023, 2022 and 2021 were $23.550, $37.388 and $89.528 respectively, and current liabilities as at March 31, 2023, 2022 and 2021 were $41.034, $30.317 and $34.809 respectively.



    NON-GAAP FINANCIAL PERFORMANCE MEASURES

    The Company uses one adjusted financial measure, Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") to assess its operating performance. This non-GAAP financial measure is presented in a consistent manner, unless otherwise disclosed. The Company uses this measure for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. The measure also helps the Company to plan and forecast for future periods as well as to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to its GAAP financial statements, allows them to see the Company's results through the eyes of Management, and to better understand its historical and future financial performance. Neptune's method for calculating Adjusted EBITDA may differ from that used by other corporations.

    A reconciliation of net loss to Adjusted EBITDA is presented below.

    ADJUSTED EBITDA

    Although the concept of Adjusted EBITDA is not a financial or accounting measure defined under US GAAP and it may not be comparable to other issuers, it is widely used by companies. Neptune obtains its Adjusted EBITDA measurement by excluding from its net loss the following items: net finance costs (income), depreciation and amortization, and income tax expense (recovery). Other items such as equity classified stock-based compensation, non-employee compensation related to warrants, impairment losses on non-financial assets, revaluations of derivatives, costs related to conversion from IFRS to US GAAP and other changes in fair values are also added back to Neptune's net loss. The exclusion of net finance costs (income) eliminates the impact on earnings derived from non-operational activities. The exclusion of depreciation and amortization, stock-based compensation, non-employee compensation related to warrants, impairment losses, revaluations of derivatives and other changes in fair values eliminates the non-cash impact of such items, and the exclusion of costs related to conversion from IFRS to US GAAP, together with the other exclusions discussed above, present the results of the on-going business. From time to time, the Company may exclude additional items if it believes doing so would result in a more effective analysis of underlying operating performance. Adjusting for these items does not imply they are non-recurring. For purposes of this analysis, the Net finance costs (income) caption in the reconciliation below includes the impact of the revaluation of foreign exchange rates.

    In the quarter ended September 30, 2022, the Company recast comparative Adjusted EBITDA to conform to the current definition. As a result, the following adjustments were removed in the current and comparative quarters: litigation provisions, business acquisition and integration costs, signing bonus, severance and related costs, D&O insurance and write-down of inventories and deposits.

    Adjusted EBITDA1 reconciliation, in millions of dollars





    Three-month periods ended



    Twelve-month periods ended





    March 31,

    2023



    March 31,

    2022



    March 31,

    2023



    March 31,

    2022





    0



    Recasted







    Recasted



















    Net loss for the year



    $(44.513)



    $(36.662)



    $(88.803)



    $(84.425)

    Add (deduct):

















    Depreciation and amortization



    0.843



    1.656



    3.234



    6.791

    Revaluation of derivatives



    1.374



    1.672



    (14.710)



    (7.035)

    Net finance costs



    1.166



    1.266



    3.823



    2.823

    Equity classified stock-based compensation



    0.671



    1.565



    3.504



    7.817

    Non-employee compensation related to warrants



    —



    —



    —



    0.179

    System migration, conversion, implementation



    —



    (0.001)



    —



    0.327

    Impairment loss on long-lived assets



    27.511



    17.177



    53.292



    19.581

    Costs related to conversion from IFRS to US GAAP



    —



    0.577



    —



    0.577

    Change in revaluation of marketable securities



    —



    —



    —



    0.107

    Income tax recovery



    (0.015)



    (0.012)



    —



    —

    Adjusted EBITDA1



    $(12.963)



    $(12.762)



    $(39.660)



    $(53.258)

    1 The Adjusted EBITDA is not a standard measure endorsed by US GAAP requirements. In the quarter ended September 30, 2022, the Company recasted comparative Adjusted EBITDA to conform to its current definition. As a result, the following adjustments were removed in the current and comparative quarters: litigation provisions, business acquisition and integration costs, signing bonus, severance and related costs, and write-down of inventories and deposits

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neptune-reports-fiscal-fourth-quarter-and-full-year-2023-financial-results-301879056.html

    SOURCE Neptune Wellness Solutions Inc.

    Get the next $NEPT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEPT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEPT
    SEC Filings

    View All

    Neptune Wellness Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Neptune Wellness Solutions Inc. (0001401395) (Filer)

    5/6/24 2:26:26 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Neptune Wellness Solutions Inc.

    25-NSE - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    4/25/24 9:09:07 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Wellness Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K - Neptune Wellness Solutions Inc. (0001401395) (Filer)

    4/12/24 5:02:21 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Neptune Securities Settlement Fund sold $13,601 worth of shares (200,300 units at $0.07), decreasing direct ownership by 25% to 1,048,334 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    4/30/24 12:01:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Securities Settlement Fund sold $35,224 worth of shares (81,814 units at $0.43), decreasing direct ownership by 7% to 1,671,302 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    3/6/24 11:04:07 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Securities Settlement Fund sold $187,949 worth of shares (247,604 units at $0.76), decreasing direct ownership by 12% to 1,778,380 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    11/30/23 5:26:53 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neptune Appoints Interim President and CEO and Interim COO

    LAVAL, QC / ACCESSWIRE / March 8, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced the Company's Board of Directors has named Board member Michael De Geus Interim President and Chief Executive Officer, effective immediately. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals, Inc. ("Biodroga"), Interim C

    3/8/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Decision of Nasdaq Hearings Panel To Delist Common Shares

    LAVAL, QC / ACCESSWIRE / March 6, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced an update on the status of its appeal against the determination of the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") to delist the Company's common shares ("Common Shares").As previously disclosed, the Company had been notified by Nasdaq on November 30, 2023 that it was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below US$1.00 for 30 consecutive trading days and that it was not in comp

    3/6/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Michael Cammarata's Resignation Effective February 23, 2024

    LAVAL, QC / ACCESSWIRE / March 4, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced that Michael Cammarata has resigned from his role as President and Chief Executive Officer effective February 23, 2024. We thank Michael for his service and wish him best of luck in his future endeavors.About Neptune Wellness Solutions Inc.Neptune is a consumer-packaged goods company that aims to innovate health and wellness products. Founded in 1998 and headquartered in Laval, Quebec with a United States headquarters in Jupiter, Florida, the company focuses on developing a portfolio of high-quality, affordable consumer products that align with the latest marke

    3/4/24 8:31:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Leadership Updates

    Live Leadership Updates

    View All

    Neptune Appoints Interim President and CEO and Interim COO

    LAVAL, QC / ACCESSWIRE / March 8, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced the Company's Board of Directors has named Board member Michael De Geus Interim President and Chief Executive Officer, effective immediately. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals, Inc. ("Biodroga"), Interim C

    3/8/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Reports Fiscal Third Quarter 2024 Financial Results

    LAVAL, QC / ACCESSWIRE / February 16, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced its financial and operating results for its fiscal third quarter 2024 ending December 31, 2023.Recent Business HighlightsAnnounced the appointment of Stifel Nicolaus Canada Inc. ("Stifel") to act as exclusive financial advisor to the Company's organic baby food and toddler brand, Sprout Foods Inc. ("Sprout Organics"), providing financial advisory, investment banking services, and strategic advice regarding the review of divestiture alternatives related

    2/16/24 5:35:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Retains Stifel to Explore Strategic Alternatives for Sprout Organics

    LAVAL, QC / ACCESSWIRE / January 24, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced the appointment of Stifel Nicolaus Canada Inc. ("Stifel") to act as exclusive financial advisor to the Company's organic baby food and toddler brand, Sprout Foods Inc. ("Sprout Organics"), providing financial advisory, investment banking services, and strategic advice regarding the review of divestiture alternatives related to Sprout Organics.Stifel brings a wealth of experience and expertise in the financial sector, having successfully facilitated nume

    1/24/24 9:00:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Financials

    Live finance-specific insights

    View All

    Neptune Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results

    Consolidated revenues for fiscal 2023 totaled $52.6 million, an increase of $3.8 million or 7.8% as compared to $48.8 million for fiscal 2022 Q4 net sales $12.1 million, up 5% from last year's $11.5 million Sprout maintained a top 3 brand position on Amazon in fiscal 2023 and strong sales levels in all periods nationally1 Sprout was available in 90% of footprint the Organic Baby Food market across all 50 U.S. states and Canada Company to host a conference call at 5:00 p.m. (Eastern Time) on Tuesday, July 18, 2023 LAVAL, QC, July 17, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustai

    7/17/23 5:38:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune to Report Fiscal Third Quarter 2023 Financial Results on March 30, 2023

    Company to host a conference call at 5:00 p.m. (Eastern Time) LAVAL, QC, March 30, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, announced today that it will report its financial results for the third quarter of fiscal 2023 after the market close on Thursday, March 30, 2023. The Company will host a conference call at 5:00 p.m. (Eastern Time) today, Thursday, March 30, 2023, to discuss these results. The conference call wil

    3/30/23 11:28:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Receipt of NASDAQ Notification

    LAVAL, QC, Feb. 24, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT) ), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced that the Company has received written notification from the Listing Qualification Department of the Nasdaq Stock Market LLC on February 23, 2023, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), as a result of Neptune not having timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022 with the U.S. Securities and Exchange Commission.  

    2/24/23 4:05:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Neptune Wellness Solutions Inc. (Amendment)

    SC 13G/A - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    2/12/24 6:48:47 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Neptune Wellness Solutions Inc. (Amendment)

    SC 13G/A - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    1/2/24 2:02:04 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Neptune Wellness Solutions Inc.

    SC 13D - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    10/17/23 11:57:17 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care